147 related articles for article (PubMed ID: 37370714)
1. The Application of GHRH Antagonist as a Treatment for Resistant APL.
Chale RS; Almeida SM; Rodriguez M; Jozic I; Gaumond SI; Schally AV; Jimenez JJ
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370714
[TBL] [Abstract][Full Text] [Related]
2. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI; Abdin R; Costoya J; Schally AV; Jimenez JJ
Oncotarget; 2024 Apr; 15():248-254. PubMed ID: 38588464
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
4. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
[TBL] [Abstract][Full Text] [Related]
5. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
7. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
Jimenez JJ; DelCanto GM; Popovics P; Perez A; Vila Granda A; Vidaurre I; Cai RZ; Rick FG; Swords RT; Schally AV
Br J Haematol; 2018 May; 181(4):476-485. PubMed ID: 29663325
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
[TBL] [Abstract][Full Text] [Related]
9. Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide.
Borges GSM; Sicard P; de Mello Gomides Loures C; Evangelista FGC; Sales CC; de Paula Sabino A; Fernandes C; Ferreira LAM; Richard S
AAPS PharmSciTech; 2023 Mar; 24(3):79. PubMed ID: 36918482
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
[TBL] [Abstract][Full Text] [Related]
11. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells.
de Almeida LY; Pereira-Martins DA; Weinhäuser I; Ortiz C; Cândido LA; Lange AP; De Abreu NF; Mendonza SES; de Deus Wagatsuma VM; Do Nascimento MC; Paiva HH; Alves-Paiva RM; Bonaldo CCOM; Nascimento DC; Alves-Filho JC; Scheucher PS; Lima ASG; Schuringa JJ; Ammantuna E; Ottone T; Noguera NI; Araujo CL; Rego EM
Front Oncol; 2021; 11():686445. PubMed ID: 34650910
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study.
Perez R; Schally AV; Popovics P; Cai R; Sha W; Rincon R; Rick FG
Oncoscience; 2014; 1(10):665-73. PubMed ID: 25593995
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
14. Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
Atashrazm F; Lowenthal RM; Dickinson JL; Holloway AF; Woods GM
Oncotarget; 2016 Jul; 7(29):46028-46041. PubMed ID: 27329592
[TBL] [Abstract][Full Text] [Related]
15. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
16. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
17. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between hnRNP K and SET in ATRA-induced differentiation in acute promyelocytic leukemia.
Padovani KS; Goto RN; Fugio LB; Garcia CB; Alves VM; Brassesco MS; Greene LJ; Rego EM; Leopoldino AM
FEBS Open Bio; 2021 Jul; 11(7):2019-2032. PubMed ID: 34058077
[TBL] [Abstract][Full Text] [Related]
19. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
[TBL] [Abstract][Full Text] [Related]
20. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
